STOCK TITAN
  1. Home
  2. Sec-filings
  3. VCYT
  4. [Form 4] VERACYTE, INC. Insider Trading Activity

Veracyte officer sells 13,110 shares in plan

Veracyte’s Chief Scientific & Medical Officer reported pre-planned stock sales plus tax-withholding share dispositions tied to RSU vesting.

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

VERACYTE, INC. (VCYT) reported that Chief Scientific & Med Officer Phillip G. Febbo sold common stock in planned transactions and had shares withheld for taxes. On September 4, 2026, he sold 10,405 shares at $42.8933 per share and 2,705 shares at $43.6618 per share in open-market or private transactions pursuant to a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,639 shares at $44.88 per share were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, which the company states does not represent a sale.

Positive

  • None.

Negative

  • None.
Insider Febbo Phillip G.
Role Chief Scientific & Med Officer
Sold 13,110 shs ($564K)
Type Security Shares Price Value
Sale Common Stock F2, F3 10,405 $42.8933 $446K
Sale Common Stock F2, F4 2,705 $43.6618 $118K
Tax Withholding Common Stock F1 3,639 $44.88 $163K
Holdings After Transaction: Common Stock — 133,048 shares (Direct)
Footnotes (4)
  1. F1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
  2. F2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
  3. F3. Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  4. F4. Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Shares sold September 4, 2026 (lot 1) 10,405 shares at $42.8933 per share Open-market or private sale of Veracyte common stock by Phillip G. Febbo
Shares sold September 4, 2026 (lot 2) 2,705 shares at $43.6618 per share Open-market or private sale of Veracyte common stock by Phillip G. Febbo
Total shares sold on September 4, 2026 13,110 shares Aggregate of the two reported sale transactions
Shares withheld for taxes September 2, 2026 3,639 shares at $44.88 per share Shares withheld to satisfy tax withholding obligations on RSU vesting, not a sale
Rule 10b5-1 plan adoption date August 21, 2025 Plan under which the September 4, 2026 sales were executed
Rule 10b5-1 plan regulatory
"transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"in connection with the vesting of certain restricted stock units on September 2, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sales price financial
"Represents weighted average sales price. Sale prices for the transactions range"
tax withholding obligations financial
"shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations"

FAQ

What insider transactions did Veracyte (VCYT) report for Phillip G. Febbo?
Veracyte reported that Phillip G. Febbo sold 10,405 shares at $42.8933 and 2,705 shares at $43.6618 on September 4, 2026, and had 3,639 shares at $44.88 withheld on September 2, 2026 to cover tax obligations from RSU vesting.

Were the September 4, 2026 Veracyte (VCYT) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the September 4, 2026 transactions were made pursuant to a Rule 10b5-1 plan adopted on August 21, 2025, indicating the sales were pre-arranged under that trading plan.

Does the September 2, 2026 transaction for Veracyte (VCYT) represent an open-market sale?
No. The Form 4 explains that 3,639 shares on September 2, 2026 represent shares withheld to satisfy tax withholding obligations related to RSU vesting and do not represent a sale.

How many Veracyte (VCYT) shares did Phillip G. Febbo sell in total on September 4, 2026?
On September 4, 2026, Phillip G. Febbo sold a total of 13,110 shares of Veracyte common stock, consisting of 10,405 shares at $42.8933 and 2,705 shares at $43.6618 per share.

What price information did Veracyte (VCYT) disclose for the September 4, 2026 insider sales?
For September 4, 2026, the Form 4 reports weighted average sales prices: $42.8933 per share for 10,405 shares, with individual prices from $42.47 to $43.47, and $43.6618 per share for 2,705 shares, with individual prices from $43.475 to $44.16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Febbo Phillip G.
(Last)(First)(Middle)
6000 SHORELINE COURT, SUITE 300
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific & Med Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/02/2026F(1)3,639D$44.88146,158D
Common Stock09/04/2026S(2)10,405D$42.8933(3)135,753D
Common Stock09/04/2026S(2)2,705D$43.6618(4)133,048D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
3. Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
4. Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact09/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR